The CAP accreditation plan is an internationally-recognized system that uses even more rigorous standards than regulatory compliance to greatly help labs achieve the best standard of excellence. In order to be eligible for accreditation, labs must perform proficiency assessment on needed analytes. ‘MLE is quite proud to experienced our plan reviewed by CAP and to have almost 100 of our provided analytes accepted by their LAP plan,’ stated MLE Director Connie Laubenthal. ‘Using the LAP, or similar program, ensures your lab includes a good quality assurance program. Likewise, MLE has constantly had the best of standards in providing quality materials to your participants and we pride ourselves on our standard of excellence in digesting and analyzing the data received from our participant laboratories.’ The full listing of tests recognized by CAP’s LAP plan is located at MLE’s objective is to manage a service-oriented proficiency testing program that provides technical and educational equipment necessary to assess, monitor, and improve the quality of laboratory testing.Corporate advancements – April 20, 2010: Completion of a $15.0 million registered direct offering with certain institutional investors. April 23 -, 2010: Regained compliance with Nasdaq’s minimum bid cost listing requirement. – June 21, 2010: Completion of a $12.1 million registered direct offering with certain institutional investors. After Quarter-End – July 8, 2010: Demonstration at the 7th International Congress of Neuroendocrinology in Rouen, France, of a scientific poster entitled, Use of the Orally Active Ghrelin Mimetic AEZS-130 as a Simple Test for the Diagnosis of Growth Hormone Deficiency in adults . – July 14, 2010: Perifosine receives orphan drug designation by the FDA for the treating neuroblastoma, a tumor of the nervous program affecting mostly children and infants that there are no FDA approved treatments.